Viewing Study NCT01137994


Ignite Creation Date: 2025-12-25 @ 1:27 AM
Ignite Modification Date: 2026-02-01 @ 3:26 AM
Study NCT ID: NCT01137994
Status: WITHDRAWN
Last Update Posted: 2013-03-13
First Post: 2010-06-03
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
Sponsor: GlaxoSmithKline
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neoplasms, Breast View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ErbB2 View
None Trastuzumab View
None p95HER2 View
None Metastatic Breast Cancer View
None HER2 View
None Lapatinib View